Eli Lilly and Company (LLY)
| Market Cap | 1.01T +46.8% |
| Revenue (ttm) | 72.25B +47.4% |
| Net Income | 25.28B +127.6% |
| EPS | 28.15 +129.1% |
| Shares Out | 891.74M |
| PE Ratio | 40.19 |
| Forward PE | 30.34 |
| Dividend | $6.92 (0.61%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 4,125,583 |
| Open | 1,142.97 |
| Previous Close | 1,125.27 |
| Day's Range | 1,131.03 - 1,166.29 |
| 52-Week Range | 623.78 - 1,166.29 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 1,215.10 (+7.4%) |
| Earnings Date | Apr 30, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 31 analysts, the average rating for LLY stock is "Buy." The 12-month stock price target is $1,215.1, which is an increase of 7.40% from the latest price.
News
Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits
Drugmaker Eli Lilly presented trial results to medical professionals on Saturday showing its next-generation obesity drug retatrutide curbed sleep apnea severity in addition to boosting weight loss ...
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity In addition to we...
Jim Cramer Sees Eli Lilly (LLY) Delivering ‘Knockout Punch’ to Competitors
The company recently launched a new pill version of its weight-loss drug.
No tech, no problem. Dow makes record and traders think these stocks can lead now
Traders bought about 5,300 calls in the State Street Health Care Select Sector SPDR ETF (XLV) on Thursday, compared to just over 1,000 puts, according to data from ThinkOrSwim.
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it's in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes h...
Lilly to halve planned €2.3 billion investment in Germany, CEO tells newspaper
Eli Lilly will halve its originally planned investment of €2.3 billion ($2.67 billion) in Germany, CEO Dave Ricks told the Handelsblatt business daily.
‘Expect More Acquisitions,’ Says Eli Lilly’s (LLY) Top Dealmaker
The company has been on a buying spree this year.
Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs
Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its gene-editing technology with pharma major Eli Lilly , worth up to $1.9 billion, to develop new therapies for rare inher...
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
Eli Lilly's Jacob Van Naarden says Lilly is using the financial strength from its GLP-1 drugs like Mounjaro and Zepbound to fund its new dealmaking strategy. Van Naarden recently became Lilly's head o...
Focus: GLP-1 drugs may have a beneficial effect across many types of cancer
A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide protection against many types of cancer.
Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.
The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become apparent this year.
Exclusive: Cigna drops coverage of GLP-1 obesity drugs for its own employees
Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee health plan effective July 1, according to materials viewe...
Eli Lilly issues data sharing ultimatum to hospitals, Fierce Healthcare reports
Eli Lilly (LLY) plans to stop providing 340B discounted drug pricing to certain hospitals that have not complied with its claims data reporting requirements introduced on February 1, a move…
Eli Lilly to spotlight hematology portfolio at EHA Annual Meeting
Eli Lilly (LLY) and Company announced the details of presentations at the European Hematology Association Annual Meeting, taking place June 11-14 in Stockholm, Sweden. Data to be highlighted include a...
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
Positive results from the Phase 3 BRUIN CLL-322 study comparing time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL...
Eli Lilly Signs Licensing Deal for Intestinal Treatment
The medication treats bowel conditions.
Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals
U.S. drugmaker Eli Lilly has entered into an agreement to collaborate on and possibly licence experimental medicines from a unit of Haisco Pharmaceutical Group , with potential payments of up to aro...
Eli Lilly announces Phase 3 Libretto-432 trial of Retevmo met primary endpoint
Eli Lilly (LLY) and Company announced results from the Phase 3 Libretto-432 clinical trial of Retevmo as adjuvant therapy versus placebo in patients with early-stage rearranged during transfection fus...
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring ...
Lilly's Mounjaro tops other GLP-1s for some type 2 diabetes patients
We also report on two studies with findings that could bring eventual relief for patients still struggling with long COVID symptoms.
Lilly's GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans
That means millions more Americans may get access to Lilly's new GLP-1 pill Foundayo or the GLP-1 injection Zepbound.
Eli Lilly and Company Transcript: Bernstein 42nd Annual Strategic Decisions Conference
The event highlighted a differentiated, long-term R&D strategy, rapid drug development, and a robust pipeline in obesity, neuroscience, and genetic medicine. AI and proprietary data are key competitive advantages, while early-stage acquisitions and direct-to-patient models support future growth.
Lilly to present new Foundayo, Mounjaro and retatrutide data at ADA meeting
Eli Lilly (LLY) will present new data across its cardiometabolic portfolio at the American Diabetes Association’s 86th Scientific Sessions taking place June 5-8 in New Orleans. “Together, these findin...
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to redefi...